US 9603922
Modulation of NKT cell activity with antigen-loaded CD1d molecules
granted A61KA61K2039/55516A61K2039/55561
Quick answer
US patent 9603922 (Modulation of NKT cell activity with antigen-loaded CD1d molecules) held by VACCINEX, INC. expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- VACCINEX, INC.
- Grant date
- Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K2039/55516, A61K2039/55561, A61K2039/55572, A61K2039/55594